Innovation is the Key Benchmark, Focus on Four Healthcare Industry Sub-Sectors in 2023, Says Jafar Wang of Legend Capital ACN Newswire

Innovation is the Key Benchmark, Focus on Four Healthcare Industry Sub-Sectors in 2023, Says Jafar Wang of Legend Capital

February 15, 2023
HONG KONG, Feb 15, 2023 - (ACN Newswire via SEAPRWire.com) - Legend Capital invested in 29 healthcare companies that officially disclosed financing rounds in 2022, according to the VBDATA Database. Since 2007, Legend Capital has continuously invested in healthcare across industry sub-sectors including innovative drugs, biotechnology, medical devices, diagnostic technology, professional services and supply chain. Overtime, it has built a powerful healthcare ecosystem encompassing more than 140 portfolio companies. Through value-added initiatives including strategic management and business empowerment activities, Legend Capital has the capability to bring far more value to the table in addition to financial resources.Breakthrough and global innovations are the key benchmarks by which Legend Capital judges and selects projects in a changing external environment. How did Legend Capital navigate the challenges of 2022 and how does it see the market in 2023? What are the key healthcare investment themes? In an interview with VCBeat, Jafar Wang, Co-Chief Investment Officer of Legend Capital, shared his perspectives:"Five significant changes in primary market investments"Legend Capital observed several important evolvements in the healthcare investment market during 2022:First, the industry's overall investment pace slowed down, with considerable decrease in deal count, deal size, and the speed of decision-making. Activity level of the healthcare investment market has returned to normalcy after an overheated period of 2020-2021, which now appears on the same level as 2019. Second, there has been significant changes in investors' selection criteria. Institutional investors need to evaluate whether a project has demonstrated breakthrough innovation, whether it is among the top three in its field, and whether it has the potential to compete on the global stage for first-in-class or best-in-class status. As a result, investors look to sector leaders for investment opportunities.Third, there is growing emphasis on exit and exit management.Fourth, emerging markets are receiving more attention as industry participants turn their overseas focus from developed markets to emerging economies. On the one hand, investors have increased their allocation to emerging markets, such as Legend Capital's expansion into Southeast Asia. Similarly, more players are aggressively expanding abroad in the hope that their products and services will reach the wider emerging markets. For Chinese healthcare companies, these markets will be a key destination in the next five to ten years.Lastly, there is general awareness in the industry that the window for biotech companies to transition into biopharma has closed for the moment. Biotech companies should continue to focus on their core competencies in technology innovation and product development, while actively pursue collaborations in manufacturing, supply chain, and downstream commercialization with top-tier industry players."An investment strategy focused on innovation and early-stage opportunities" Regardless of changes to the external environment, Legend Capital continues to uphold the importance of being an investor in value, innovation, in early-stage firms, in core technologies, and taking the long view. Our selection criteria for deals remain consistently high.In 2022, Legend Capital established a Frontier Biotechnology Fund to invest in innovative seed and start-up stage biotechnology and MedTech companies. Although such investments carry higher risks, they could potentially create game-changing results for the industry. This fund will mainly focus on the commercialization of ideas and products from academia, overseas returnees, and well-known spin-off teams or founders. Legend Capital values cutting-edge, innovative, and disruptive technologies, and we are willing to make bigger bets and dedicate more resources towards these seed and angel stage projects.Legend Capital is also devoted to investing in the independence and security of the healthcare supply chain. Two years ago, we put forward the view that an independent and secure supply chain, as well as import substitution, are among the best investment opportunities over the next five years. We are not only focused on the China market, but with an eye to the international potential of investee companies. The idea of supply chain investment is to help resolve bottlenecks faced by the industry while also serving the global market.In terms of Legend Capital's healthcare ecosystem, we are continuously expanding this ecosystem and improving synergies within. In the past, our value-added services were geared towards management guidance, but two years ago, we increased efforts to empower our portfolio companies with industry perspectives. To date, Legend Capital has invested in more than 140 healthcare companies, and established a complete, one-stop value-added service system across research, production, supply chain, and commercialization function. Our presence in sub-sectors from life science tools to preclinical research, clinical CRO, manufacturing and commercialization allow Legend Capital to bring synergy to portfolio companies. As this value-add ecosystem evolve and portfolio companies reap the benefits, oftentimes prospective investees become more receptive to our investment; they see Legend Capital as an investor with abundant industry resources, rather than a pure financial investor.Additionally, Legend Capital cooperates closely with industry-leading firms to bring additional resources to our healthcare ecosystem, which helps portfolio companies in their business development. Through product licensing and strategic collaborations, we have strengthened the connection among the ecosystem, portfolio companies, and industry peers. Working with healthcare companies in the industry not only aids the development of our portfolio companies, but also present potential new opportunities for Legend Capital. For instance, we have been able to generate new investments with our industry partners through efforts such as co-investments, incubation, and spin-offs. This may very well become a common investment practice in the future.Throughout 2022, Legend Capital had five healthcare-related IPOs, including Recbio Technology, R&G Pharmastudies, MicuRx Pharmaceutical, Sipai Health Technology, and Lunit; in addition, nearly 10 portfolio companies were exited through M&A. A RMB 300+ million GP-led secondary transaction was completed during the year after concluding a $270 million one in 2021. We will continue to utilize secondary tools in the future to generate large-scale exits for existing LPs, which also create opportunities to partner with new LPs while supporting our portfolio companies on their journeys, to ultimately achieve a win-win for all parties."Opportunities are bred from innovation" Legend Capital maintains a diversified portfolio of companies in innovative drugs and biotechnology, medical devices and diagnostic technology, professional service and supply chain, and will continue to actively invest going forward. In 2023, our healthcare investment efforts will focus on three main areas.For biotech, Legend Capital will concentrate on small nucleic acid medicines and CGT-related verticals such as gene editing and induced pluripotent stem cells. In MedTech, more focus will be placed on life science tools, import substitution, and consumer healthcare. In professional services and supply chain, with the evolvement of CGT and small nucleic acid pharmaceuticals, CRO and CDMO may present new investment prospects. In addition to investing in pharmaceutical CRO and CDMO, Legend Capital saw success in 2022 with investments in medical device and diagnostic CRO and CDMO so we will continue to invest in these fields.Leveraging our vast portfolio ecosystem, Legend Capital will continue to make significant investments in supply chain independence, including upstream consumables, machinery, and life science tools. To achieve the best outcomes, Legend Capital will collaborate with its leading portfolio companies in the future on co-investments and help them with potential M&A opportunities.In summary, Legend Capital believes that the best investment opportunities arise from breakthrough innovation. For instance, our portfolio company Harbour BioMed recently announced that the U.S. FDA has cleared the IND application to commence clinical trials of its globally first-in-class fully human monoclonal antibody HBM1020 targeting B7H7 (also known as HHLA2) in the U.S. HBM1020 is also the globally first-ever monoclonal antibody targeting B7H7 cleared by the regulatory agency for clinical trials. HBM1020 may present a novel anti-tumor therapeutic complementary to PD-(L)1 therapeutics to patients, especially for PD-L1 negative/refractory patients. Regardless of the outcome, we believe a company will stand a better chance to break out from intense competition when it has the courage and boldness to be the innovator.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Fujitsu and Sapporo Medical University launch joint project to realize data portability in the healthcare field JCN Newswire

Fujitsu and Sapporo Medical University launch joint project to realize data portability in the healthcare field

January 16, 2023
TOKYO, Jan 16, 2023 - (JCN Newswire via SEAPRWire.com) - Fujitsu and Sapporo Medical University today announced the launch of a joint project starting in April 2023 to realize data portability (1) for patients' healthcare data including electronic health records (EHRs) (2) and personal health records (PHRs) (3).Image 1: Overview of the initiativeImage 2: App screen image (in Japanese)As part of the joint project, Fujitsu will develop a mobile app that enables users to view healthcare data on their iPhones (4) and a cloud-based healthcare data platform to manage patients' health data. This project marks the first initiative in Japan to link electronic medical records with Apple's Health app under Apple's support.EHR data stored on the newly developed external healthcare data platform will be converted to a format in accordance with JP Core (FHIR JP Core Implementation Guide Version 1.1.1) (5), the latest Japanese guideline under the next generation standards framework HL7 FHIR for health information exchange.By empowering patients to access their medical data from anywhere at any time and play a more active role in managing their own health, the project aims to contribute to the provision of optimal medical care and services tailored to the health conditions of individual patients while simultaneously improving patient engagement (6).Sapporo Medical University Hospital, the affiliated hospital of Sapporo Medical University, aims to introduce the system in April 2023.BackgroundJapan currently faces increasing demographic pressures as it confronts the challenges posed by one of the oldest populations in the world. In addition to medical services, the usage of medical health data in patients' individual health management represents an important issue both for patients and their families. To enable patients as well as medical providers to more easily manage medical data, many countries world-wide are implementing national standards under the HL7 FHIR (Fast Healthcare Interoperability Resource) framework designed to enable the rapid exchange of healthcare-related information, including medical records and other patient data. Many of these initiatives also increasingly promote the use of smartphone apps for health management.In Japan, however, the scope of use of EHRs and other schemes that allow patients to manage health data on mobiles devices remains limited. To this end, in recent years the Japanese government and relevant ministries started to examine measures (7) to implement a framework whereby patients can manage both EHRs issued by medical institutions and their own vital data by themselves.Fujitsu, which has been working to standardize EHRs and develop secure cloud technologies, and Sapporo Medical University, which has been working to improve the quality of advanced medical care in the Hokkaido area, launched a joint project using healthcare data at Sapporo Medical University Hospital to realize data portability in the healthcare field.About the joint project1. OverviewAs part of their collaboration, Fujitsu and Sapporo Medical University aim to develop a cloud-based healthcare data platform to manage patient data and a system that enables patients to view their personal health information such as EHRs from anywhere at any time on their smartphones.By storing patients' EHRs and vital data on the healthcare data platform and providing access to the data, Sapporo Medical University Hospital aims to improve the quality of medical services based on a detailed understanding of patients' health conditions. Fujitsu will develop a smartphone app to access JP Core-compliant cloud-based EHRs issued by Sapporo Medical University Hospital, as well as a cloud-based healthcare data platform to manage patient data. On the app, patients will be able to choose whether they want to store their data externally and to decide about the scope of usage of their personal and healthcare data. In accordance with patients' consent settings, Fujitsu will store information from patients' EHRs and vital data measured by their iPhones or Apple Watches (4) in a healthcare data base. Fujitsu will develop the new app using Apple's "HealthKit" (4) framework and will receive Apple's technical support within this initiative.Using the new system, patients will be able to check past medical information they received from hospitals, including test results and medication prescriptions on the app as part of their individual health management.2. Roles and responsibilitiesFujitsu- Construction of a scheme to convert medical data into HL7 FHIR format- Development and provision of smartphone app for patients to view EHRs- Establishment of a system for consent acquisition and management that enables patients to decide about the use of their healthcare data- Provision of healthcare data platform to manage EHRs, vital data, and other dataSapporo Medical University Hospital- Assistance in development of system to convert medical data into HL7 FHIR format- Support of system design during app development from medical field viewpoint- Improvement of the quality of healthcare through the use of healthcare data in clinical practice- Examination of a new regional healthcare model using a healthcare data platform- Supervision of system design and operation of the new system in the hospital- Promotion of the new app to patientsFuture PlansMoving forward, Fujitsu and Sapporo Medical University will examine additional ways to further utilize healthcare data and realize data portability, and plan to draw on data from multiple medical institutions to build a framework for advanced regional medical cooperation with medical institutions in Hokkaido in Japan.Sapporo Medical University Hospital will promote the development of an environment for the utilization of healthcare data in clinical practice. As a core hospital for regional medical care in Hokkaido, it will further expand data collaboration among hospitals in Hokkaido and promote the provision of advanced medical care tailored to each patient based on more detailed PHRs. Sapporo Medical University further plans to use individual patients' healthcare data in R&D of AI technology for diabetes treatment at its facilities and AI research previously conducted using EHRs. Sapporo Medical University anticipates that patients' healthcare data (collected with patients' consensus) can in future be used as useful information for selecting appropriate health treatments.Fujitsu aims to provide comprehensive, personalized healthcare by combining a wide range of healthcare data with the latest digital technologies. Fujitsu will continue to promote "Healthy Living," one of its key focus areas under its global business brand Fujitsu Uvance, to help create a world that enriches the life experience of everyone.(1) Data portability:A system that allows a person to manage and freely carry information that is individually managed by governments, companies, medical institutions, etc.(2) EHR:"Electric Health Record;" here, EHR refers to integrated data for the purpose of collaborating and utilizing medical information in the various medical institutions.(3) PHR:"Personal Health Records." Data on individual health, medical care and nursing care collected and stored in an integrated manner.(4) iPhone, Apple Watch, HealthKit are registered trademarks of Apple Inc. The iPhone trademark is used under the license of Aiphone Co., Ltd.(5) JP Core:Implementation Guide of the next-generation standard for health information exchange HL7 FHIR in Japan (FHIR JP Core Implementation Guide V 1.1.1). HL7 FHIR stands for HL7 (Health Level Seven) Fast Healthcare Interoperability Resource and is a next-generation standard created by the HL7 organization. Health Level Seven, Inc. is an organization dedicated to developing and promoting standards for healthcare information. Standards for healthcare information are established to provide data interoperability in the medical field. HL7 FHIR JP Core refers to the Japanese implementation guide "FHIR JP Core Implementation Guide V 1.1.1," that defines minimum compatibility requirements for accessing patient data in Japan based on the HL7 FHIR standard, which is certified by HL7 Japan (Japanese branch of the HL7 organisation) and created by the NeXEHRS Research Group "FHIR Japanese implementation research working group in Japan Association of Medical Informatics (JAMI)".(6) Patient engagement:Active engagement of patients and their families in gathering information and decision making about their health symptoms, diseases, and treatment methods.(7) Measures examined by the Japanese government and ministries: The "Basic Policies for Economic and Fiscal Management and Reform 2022 (Basic Policies 2022)," which was approved by the Cabinet in June 2022, also indicated a policy of emphasizing the promotion of PHR and the utilization of medical information as a national strategy. www.mhlw.go.jp/content/12401000/000977520.pdf (in Japanese)About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About Sapporo Medical UniversitySapporo Medical University aims to contribute to the improvement of the welfare of communities in Hokkaido as well as to the cultural development of Humanity by teaching the theory and practical application of medicine and health sciences, conducting in-depth research and fostering students' intellect, morality and practical abilities. Sapporo Medical University Hospital has facilities in 29 clinical divisions and 938 inpatient beds. It provides advanced, state-of-the-art medical care, such as emergency medical care, cancer treatment and regenerative medicine, and also plays a significant role as a medical institution that assists the development of local medical services and accepts patients from remote areas in Hokkaido in cases of disasters. Find out more: https://web.sapmed.ac.jp/e/index.html Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Solve.Care Celebrates Remarkable Achievements, Ending 2022 on a High SeaPRwire

Solve.Care Celebrates Remarkable Achievements, Ending 2022 on a High

December 30, 2022
Tallinn, Estonia, December 30, 2022 – (SEAPRWire) – Solve.Care – a healthcare platform company that leverages blockchain to deliver better care – has successfully ended the year on a high note by demonstrating the company’s strength, resilience, and ability to overcome the challenges the crypto winter has brought. Several remarkable achievements in 2022 has helped Solve.Care set a solid foundation for the company to welcome the upcoming year with further transformation and growth. 2022 marked the start of a much dreaded “crypto winter,” resulting in the collapse of numerous well-known enterprises. Although the challenging environment had a devastating impact across the cryptocurrency industry, it has also been an opportunity for many value-based projects to prove themselves. In the last few months, toward the end of the year, Solve.Care launched a series of announcements on great advancements in their development. Following the company’s vision of redefining care coordination, streamlining access to care for all stakeholders, while empowering consumers and reducing administration costs, fraud and waste by billions, the company has shown how they are addressing the complex problems that plague healthcare around the world. One of the key highlights is the major release of Care.Wallet, a health management application that is available in the Apple App Store and Google Play Store. Care.Wallet is designed to be a life-long companion for users with the goal of gaining better control over their healthcare journey while retaining ownership of their healthcare data. The app serves as a gateway to a diverse range of Web3 healthcare networks on the Solve.Care platform and acts as a personalized healthcare administrator for individuals and providers. Through Care.Wallet, users can easily set up a Care.Circle, to connect with friends, family, and healthcare providers so that they can monitor their health in a more effective way. Commenting on Care.Wallet as one of the biggest news from Solve.Care in 2022. Pradeep Goel, CEO of Solve.Care said: “Care.Wallet represents another breakthrough in Web3 development for healthcare. It is a major milestone for Solve.Care in delivering better care for users globally. Users can rest assured in the knowledge that their data is secure and decentralized using blockchain technology no matter which healthcare network they access on our Care.Platform.” Not stopping there, on 26th December 2022, Solve.Care continued to assert its position as a pioneer in applying innovative approaches to healthcare by launching the first public Web3 Care.Network on the Solve.Care Platform using the revolutionary Care.Protocol – an immutable, decentralized application protocol that governs a Care.Network. Tracing back to 2019, the company collaborated with one of the world’s leading research-driven pharmaceutical companies – Boehringer Ingelheim – to launch a diabetes management network for more than 25,000 patients in the Arizona Care Network (ACN), a leading accountable care organization in the U.S.. The network was dedicated to the well-being of patients with type 2 diabetes, helping them manage their chronic condition, as well as optimize and coordinate care with their families and physicians. The key advantage to ensure mass accessibility and proliferation of Care.Networks on a global scale is that they can be easily authored by clinicians with unprecedented speed without the need for any complex technical Web3 or blockchain knowledge. All data is stored on decentralized individual nodes, where all interactions and transactions are automatically tokenized. Just prior to the end of 2022, Solve.Care announced the integration of the Care.Platform with QuickBooks. With the strong and long-time experience of QuickBooks in deploying electronic payment functions, online banking, and reconciliation, this integration has enabled the platform to be eCommerce ready, making it easier for users to manage the financial aspects of running a digital healthcare network. The company has consistently demonstrated its resolve in achieving its mission of making healthcare work better for the patient, providers, and business. By providing a platform that enables a complete seamless interoperable ecosystem for patient-centric care, all three pillars of healthcare – clinical, administrative and payments – are addressed. 2022 has been a remarkable year for Solve.Care. The company was awarded “Enterprise Transformation Award” at the 2022 Web3 and Blockchain Transformation Awards, “Healthtech Company of the Year” by Global Business Tech Awards, “Best Digital Leadership in Health Equity, Diversity and Inclusion” for the eHealthcare Leadership Awards, along with a host of various other awards recognizing its continuous contributions to both the healthcare and the blockchain and crypto industries. Building on all these advancements made in 2022, it is expected that 2023 will continue to be a fruitful year for the global blockchain healthcare company when its major healthcare clients adopt the Care.Platform to roll out digital healthcare networks. With clients such as insurance companies, hospitals, employers, and government agencies, the economic effect on healthcare costs is expected be significant when all these clients author and operate their own Care Networks. It is also expected that the SOLVE token, an ERC20 token, and the utility token for the Solve.Care Platform, will garner greater utility as more clients adopt the Care.Platform. The token enables a global payment system on the Solve.Care Platform and creates a unique ecosystem between healthcare providers, developers, government programs, B2B clients, patients and more. In the Solve.Care ecosystem, the token is used as Gas, Fee, and Payment. Ever since entering the market in 2017, Solve.Care has proven that it was not drawn to blockchain due to the hype but because of the understanding of how the technology can bring viable, beneficial and cost-effective solutions to healthcare. The goal of improving global public health is what inspires and drives all working at Solve.Care. The company is on the right track to continue improving global healthcare and blockchain industry in 2023 and all the coming years. About Solve.Care Solve.Care is the creator of a healthcare relationship management platform that uses blockchain to redefine care coordination, improve access to care, reduce benefit administration costs, streamline payments, and help reduce fraud and waste in healthcare around the world. The Care.Platform allows for the quick and cost-effective creation and deployment of decentralized digital health networks called Care,Networks, for patient-centric care based on medical conditions, economic and social needs, and other tailored eligibility criteria, creating an entire healthcare ecosystem. It is also the first company in the world to successfully deploy digital currency and blockchain technology for value-based healthcare payments. Solve.Care is a multiple award-winning company, receiving accolades such as: ‘Enterprise Transformation Award’ at the 2022 Web3 and Blockchain Transformation Awards, ‘Corporate Wellness Software of the Year’ at the 2022 Innovatech Awards, BRI’s ‘Industry Solution of the Year 2020’, SSOW Impact Award’s ‘Technology of the Year 2020’, and many more. For more information, please visit https://solve.care. Social Links Twitter: https://twitter.com/Solve_Care LinkedIn: https://www.linkedin.com/company/solve-care YouTube: https://www.youtube.com/c/solvecare Telegram: https://t.me/SolveCare Media contact Brand: Solve.Care Contact: Dominic Tan, PR Manager E-Mail: dominic.tan@solve.care Website: https://solve.care/ SOURCE: Solve.Care The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
EC Healthcare wins “Best in Healthcare Sector” at IR Magazine's Greater China Awards 2022 ACN Newswire

EC Healthcare wins “Best in Healthcare Sector” at IR Magazine's Greater China Awards 2022

December 14, 2022
HONG KONG, Dec 14, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, is pleased to announce the Group has garnered the "Best in Healthcare Sector" at IR Magazine's Greater China Awards 2022.IR Magazine has honored excellence in investor relations around the world with awards which recognize companies that are leading the way for the IR community. This award is determined by the input of hundreds of analysts and portfolio managers, who give their opinions on which companies provide them with the best IR service. Winning this award showcases the Group's commitment to upholding the highest standard of investor relations and carries the weight of recognition from the entire investment community.Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group is honored to receive the "Best in Healthcare Sector" from IR Magazine Awards - Greater China 2022. This prestige Award demonstrates the recognition of our Group's efforts to achieve excellences in corporate governance, investor relations, transparency, and communication channel building. Looking forward, we will continue to spare tremendous effort with the aim of further consolidating the leading position in the healthcare market and make premium medical service affordable, attenable and sustainable. The Group wishes to excel together with our much-valued stakeholders to maximize overall welfare of our company and the greater community."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
JBM Healthcare Announces FY2023 Interim Results ACN Newswire

JBM Healthcare Announces FY2023 Interim Results

November 25, 2022
HONG KONG, Nov 25, 2022 - (ACN Newswire via SEAPRWire.com) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Group"; Stock Code: 2161), a leading branded healthcare products marketer and distributor in Hong Kong, has announced today the interim results of the Group for the six months ended 30 September 2022 (the "Reporting Period").KEY HIGHLIGHTS-- Period-on-period revenue up by 25%, totaled HK$236.8 million -- Profit attributable to equity shareholders increased by 116%, amounting to HK$21.6 million-- The Board declares an interim dividend of HK0.5 cent per share-- Proprietary Chinese medicines business witnessed robust growth of 53.1% -- Cross-border e-commerce business gained traction alongside expanded product offerings and growing customer traffic -- Foreseeable growth of traditional Chinese medicine (TCM) business bolstered by favourable policies for gaining access to Greater Bay Area markets. Despite the lingering effects of the COVID-19 pandemic and the volatile economic sentiment in Hong Kong, the Group continued to perform in a resilient manner posting total revenue of HK$236.8 million in the Reporting Period, delivering a notable increase of 25% period-on-period. Profit attributable to equity shareholders also increased by 116% period-on-period to HK$21.6 million. Such growth was primarily due to the easing of local social distancing policies, which buttressed retail spending sentiment and led to a gradual recovery of the Group's overall sales, alongside a financial subsidy from the HKSAR Government through the Employment Support Scheme.The Board declares the payment of an interim dividend for the six months ended 30 September 2022 of HK0.5 cent per share.Resilient Performance Sustained by Robust Branded PortfolioDuring the Reporting Period, the Group has made sound progress in developing its cross-border e-commerce platform, expanding the access of its products to a growing consumer base in Mainland China. Furthermore, the Group continued to implement its growth strategies to keep pace with consumer demand and market opportunities, further leveraging its unique strength to reinforce the Group's competitive position as a farsighted branded healthcare player in Asia. The promising performance was underpinned by the Group's brand management and strong commercial execution capabilities, as well as established sales network.For the branded medicines business, sales revenue saw a decline of 10.3% period-on-period to HK$56.9 million, mainly due to the adverse impact of the pandemic on retail consumption in Hong Kong and Macau Nonetheless, the category-leading AIM Atropine Eye Drops brand continued to achieve promising growth realising 11.3% sales growth.Regarding the proprietary Chinese medicines business, sales revenue delivered robust growth of 53.1%, amounting to HK$163 million, which was driven by strong momentum from its Concentrated Chinese Medicine Granules ("CCMG") business as a result of rising recognition and acceptance towards the adjunct therapeutic benefits of Chinese medicine amongst the general public. Our category leading brand, Po Chai Pills, also posted a remarkable growth of over 60% during the Reporting Period. As for health and wellness products, sales revenue registered a decline of 13.3% to HK$16.9 million during the Reporting Period, which was mainly due to lower sales of certain products in the Hong Kong retail sector, though offset by growth from Oncotype DX and the Pantogar shampoo and tonic series. Oncotype DX posted a robust growth of 19.7% with a sustained momentum during the Reporting Period. With respect to Pantogar, an effective treatment for hair loss as substantiated by clinical studies, it also gained notable success via e-commerce platforms and professional hair salon channels. Pantogar sales was boosted by the launch of a new shampoo and tonic series that feature specialised formulations for women and men.Accelerating E-commerce DevelopmentThe development of the Group's PRC cross-border e-commerce business continued to gather momentum as a result of its sustained efforts to drive expansion across product offerings, platform footholds, and customer traffic. The two self-operated flagship stores on Tmall Global Marketplace and JD Worldwide achieved significant progress in expanding market share and customer base during the Reporting Period, bolstered by the effective operation and customer service support of its dedicated cross-border e-commerce team. The Group's flagship store has earned a top 8 ranking at Tmall, while Ho Chai Kung Tji Thung San has claimed a top 5 ranking in the pain-killer category of the platform during the Reporting Period.The Group has continued to strengthen its partnership and operation with major PRC cross-border e-commerce platform customers, which witnessed a notable increase of pre-event purchase orders from B2B partners for the "6.18" and "Double 11" promotions during the Reporting Period. Apart from OTC products, the Group has been also actively enhancing its portfolio with products for tapping new potential categories to target a wider range of consumer groups. The Group's skincare and beauty products are currently sold through VIP Shop, a popular cross-border e-commerce platform for branded lifestyle products, and will be available via a growing array of cross-border e-commerce platforms.Capturing Growth Potential of Chinese MedicinesThe Group's proprietary Chinese medicine business also benefits from the government bureaus' collaborative support in facilitating the entry of Hong Kong's traditional proprietary Chinese medicines into the Greater Bay Area. Leveraging the streamlined measures for the Group's proprietary Chinese medicines portfolio to register with the Guangdong Provincial Medical Products Administration, it has successfully secured approval for registering its medicated oil brands Shiling Oil and Konsodona Medicated Oil in the Greater Bay Area.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, said, "In the wake of adverse market sentiments, pragmatism and persistence have never been more important as we navigate through the challenges that the pandemic has introduced to the business landscape. The pandemic has heightened health awareness and accelerated consumers' shift towards a more proactive approach in managing their health and wellness, which will further shore up self-care demand. The Group, as a key proprietary Chinese medicine and CCMG market player in Hong Kong, is also well poised to tap the burgeoning market in the Greater Bay Area, supported in part by favorable policies that encourage the development of TCM in the region and which will create more prospective business opportunities.Looking ahead, we remain optimistic about the outlook for the healthcare industry. Adhering to our mission of enabling better health through self-care, we will continue to focus on developing our growth strategies based on the objectives of greater resilience and operational efficiency, and capitalise on market opportunities by helping consumers better manage their health through quality and well-trusted branded healthcare products."About JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries. The Group is a unique field player with marketing expertise and a drug heritage that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Healthcare and Medical Leaders Gather to Shape the Future of Global Health ACN Newswire

Healthcare and Medical Leaders Gather to Shape the Future of Global Health

November 11, 2022
HONG KONG, Nov 11, 2022 - (ACN Newswire via SEAPRWire.com) - New research and innovations in Hong Kong and the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) are injecting new momentum and creating new opportunities for the regional and global healthcare and medical sectors, as highlighted in the two-day Asia Summit on Global Health (ASGH). The second ASGH and the physical element of the 13th edition of the HKTDC Hong Kong International Healthcare Fair concluded successfully today.The second Asia Summit on Global Health, co-organised by the Hong Kong Special Administrative Region (HKSAR) Government and HKTDC, and the physical part of the 13th HKTDC Hong Kong International Medical and Healthcare Fair conclude successfully today.Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong and Kyle Wong, PanopticAI CEO & Cofounder (R) signed a MOU on digital healthcare solution improvement on the first day of the Summit, witnessed by Patrick Lau, HKTDC Deputy Executive Director (L).As the flagship events of the first International Healthcare Week initiated by the Hong Kong Trade Development Council (HKTDC), the summit and fair attracted close to 30,000 online and physical participants from 68 countries and regions. More than 280 one-on-one Deal Flow Matchmaking sessions and 600 business meetings have also been arranged to assist participants in seizing business possibilities. Riding on this year's success, the HKTDC plans to expand International Healthcare Week in May 2023. In addition to forums and exhibitions, it plans to include more healthcare and medical-related activities to strengthen Hong Kong's position as a leading hub in this globally important industry.Dr Peter K N Lam, Chairman of the HKTDC, said, "The importance of the medical and healthcare sector to the global economy cannot be overstated, especially during the past three years. As markets across the world gradually recover from the fallout of the pandemic, the health crisis needs to be tackled in tandem. This can only be achieved through collaboration. The pandemic knows no borders and collaboration should not either. It is vital that diverse sectors and players come together and share insights and practical solutions to ensure better efficiency and sustainability in healthcare for the world."Shaping the Future of Global HealthThe ASGH is co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the HKTDC to help the industry build connections, create business opportunities and highlight the advantages of Hong Kong's healthcare and medical industries in scientific research, investment and financing as well as its trading platforms.The Summit featured more than 80 speakers, including healthcare officials and members from international organisations, scientists and medical experts, investors, business leaders, financial specialists and service providers. They shared their insights on a wide range of topics, ranging from healthcare development in Mainland China, the challenges of Ebola and COVID-19, the impact of GBA's innovation and the role of Hong Kong as both a fundraising and innovation hub. Participants also were given updates about new trends, such as the application of robotics and ethics of artificial intelligence (AI), ESG in healthcare and global challenge of mental health. At the fireside chat on the first day of the summit, Prof Peter Piot, Chief Scientific Advisor Epidemics and Special Advisor to the President of the European Commission and co-discoverer of the Ebola virus in 1976, shared his views on the challenges in creating a more sustainable future for global health and Asia's contribution to global health in the years to come.Prof Piot said: "COVID has definitely been a wake-up call to the importance of developing a sustainable and equitable healthcare system. The reality is that we are very likely entering an era of pandemics, and we must be better prepared. We must also assist the least developed countries, such as [those in] Africa and Southeast Asia, in manufacturing vaccines and other essential medications and developing the infrastructure they need to be ready for the next pandemic. I see this as a collective effort that would benefit the whole world; and everyone, including governments, businesses, civil society and individuals, should contribute in their own way."Bring New Perspectives to Universal IssuesOn the first day of the Summit, Secretary for Health Prof Lo Chung-mau remarked during the panel discussion titled "The Next Development of China's Healthcare Sector" that China had made remarkable progress in healthcare, especially in transforming treatment-oriented and hospital-based services to community-based services. Dr Donald Li, Chairman of the Elderly Commission who chaired the panel, said the high demand for healthcare services in the GBA has created many new opportunities for business and healthcare professionals.Addressing the audience of a panel discussion titled "How Innovation in the Guangdong-Hong Kong-Macau Area Reshapes Global Healthcare", speakers shared that the GBA, Shenzhen in particular, would be a new base for innovation and research amid the boom of university lab research in the city.Prof Michael Marmot, Director of the Institute of Health Equity of Department of Epidemiology and Public Health at University College London, pointed out at the thematic session titled "Adding Health to ESG: How Can Businesses Impact Health Equity?" that contribution of business and industry to healthcare was crucial. "This is because they have the capacity to improve the health and well-being of employees and customers through goods and services, whilst also making a positive impact on the communities they serve."Deal Flow Matchmarking to Facilitate Exchange and CollaborationThe Deal Flow Matchmaking on the first day connected funders from around the world with projects encompassing life sciences, medical apparatus and medicine, digital health, community health and more, with a total of 280 one-on-one meetings scheduled, of which 156 were successfully held on-site.The hybrid InnoHealth Showcase and exhibition area featured more than 180 projects and solutions from healthcare-related innovative technology enterprises, connecting them with investors around the world as well as potential business partners. A number of biotechnology and healthcare start-ups also took advantage of the Business of Healthcare Advisory Zone, receiving a full range of professional advice from investors and industry experts.PanopticAI, one of the winners of HKTDC's Start-up Express 2021, was one example of successful business matching at the Summit. The company uses patented AI and algorithm to instantly obtain health data, such as heart rate, breathing rate, blood pressure and stress index of subjects through ordinary lenses. They attended ASGH in the hope to expand to the GBA and Southeast Asia. With the support of the HKTDC, PanopticAI signed an MOU with Gleneagles Hospital Hong Kong on the first day of the Summit to further apply its research results in Hong Kong hospitals to help more people in needed.Dr Yuanyuan Yu, Assistant Professor at the School of Chinese Medicine of Hong Kong Baptist University commended the Summit's vibrant atmosphere and she was impressed by the synergy International Healthcare Week provided. The university delegation was able to meet with a lot of potential investors, business partners and academia collaborators and they anticipate further project discussions.Medical Fair Provides One-stop Platform for Industry Buyers and ProfessionalsThe 13th Hong Kong International Medical and Healthcare Fair adopted the HKTDC's new EXHIBITION+ hybrid model. Its three-day physical exhibition came to a successful close today, while the Click2Match platform that provides smart business matching to help build connections between exhibitors, buyers and industry professionals worldwide will remain active until 18 November.The fair brought together more than 300 exhibitors from different countries and regions to feature a range of the latest medical technologies and equipment, healthcare and beauty products, healthcare solutions and related services, drawing many buyers and industry professionals to source both on-site and online.Kenny Lam, Sales Manager of SWS Limited, a local exhibitor that offers textile management solutions for smart hospitals, said the Medical Fair provided a valuable platform for the company to showcase its automated uniform dispensing unit and respond to buyers' enquiries. He added: "Government officials and buyers from public and private hospitals are very interested in this system after watching our on-site demonstrations. Their feedback is overwhelming!" Additionally, they said they would support this kind of locally invented systems.Ketkanok Sasibavronyod, Senior Business Development Manager of Thailand's leading medical device distributor BJC Healthcare Company Limited, travelled to Hong Kong for the Medical Fair to source telemedicine solutions, wearables for health monitoring, medical equipment and elderly care products. She stated: "HKTDC's Click2Match smart business matching service is very useful. Thanks to it, I found and scheduled to meet in-person with two potential suppliers of elderly care equipment, VR training solutions for elderly rehabilitation and VR therapy solutions. The fair is a good place for me to see new trends in medical equipment too!"The Medical Fair is co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA). During the show, more than 10 content-rich events were held, including the highlighted HKMHDIA MedTech Forum 2022, with industry professionals keen to participate. Industry players can watch videos of the forum through the fair website.In addition to the two highlight events, the first International Healthcare Week also featured other related events, including the Gerontech and Innovation Expo cum Summit 2022, the Hong Kong Urological Association 27th Annual Scientific Meeting and the Hong Kong International Optometric Symposium.Websites- International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en- Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en- Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en- Photo download: https://bit.ly/3UwJjMIAbout HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedInMedia EnquiriesFor enquiries please contact:Asia Summit on Global HealthYuan Tung Financial Relations:Agnes Yiu, Tel: +852 3428 5690, Email: ayiu@yuantung.com.hkFung Wong, Tel: +852 3428 3122, Email: hfwong@yuantung.com.hkHKTDC's Communications & Public Affairs Department:Janet Chan, Tel: +852 2584 4369, Email: janet.ch.chan@hktdc.orgSam Ho, Tel: +852 2584 4569, Email: sam.sy.ho@hktdc.orgHong Kong International Medical and Healthcare FairHKTDC's Communications & Public Affairs Department:Frankie Leung, Tel: +852 2584 4298, Email: frankie.cy.leung@hktdc.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Spotlight on Healthcare Collaboration and Innovation at Asia Summit on Global Health and HK International Medical and Healthcare Fair ACN Newswire

Spotlight on Healthcare Collaboration and Innovation at Asia Summit on Global Health and HK International Medical and Healthcare Fair

November 10, 2022
HONG KONG, Nov 10, 2022 - (ACN Newswire via SEAPRWire.com) - Global healthcare collaboration and innovation are key themes of the Hong Kong Trade Development Council (HKTDC)'s inaugural International Healthcare Week, currently taking place at the Hong Kong Convention and Exhibition Centre (HKCEC). The week is comprised of two anchor events: the second Asia Summit on Global Health (ASGH), co-organised with the Government of the Hong Kong Special Administrative Region (HKSAR) and the 13th Hong Kong International Medical and Healthcare Fair.The second Asia Summit on Global Health, co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the HKTDC, runs under the theme "Charting a New Course in Healthcare through Collaboration" today and tomorrow.Dr Zsuzsanna Jakab, Deputy Director-General of the World Health OrganizationCao Xuetao, Vice-Minister of the National Health Commission of the People's Republic of ChinaThe two-day summit kicks off today in hybrid format under the theme of "Charting a New Course in Healthcare through Collaboration", with the second day going online. The 13th International Medical and Healthcare Fair from 9 to 11 November features more than 300 exhibitors showcasing their latest products and developments and brings together industry professionals, institutions and the research and development community. The two concurrent events are catered towards both the upstream and downstream healthcare industries and together create synergies and opportunities for medical and healthcare industry professionals as well as businesses and investors.As healthcare and the life sciences grow in importance globally, ASGH has brought together more than 80 speakers, including global business leaders and healthcare investors, science and medical experts, healthcare officials, financial specialists and professional service providers to discuss the latest trends and developments in the healthcare and medical fields. Topics covered include business opportunities and challenges for the global healthcare industry, Asia's transformational landscape in healthcare, Hong Kong's strengths in innovation and fundraising for global health as well as how the city facilitates global collaboration through partnerships to tap the opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) and beyond.John Lee, Hong Kong SAR (HKSAR) Chief Executive, spoke at the summit's opening ceremony this morning, along with Margaret Fong, Executive Director of the HKTDC, Zsuzsanna Jakab, Deputy Director-General of World Health Organization (WHO); and Cao Xuetao, Vice-Minister of the National Health Commission of the People's Republic of China. In her welcome remarks, Margaret Fong said: "The pandemic catalysed collaboration. We need to continue this momentum to pave the way to new prospects. These prospects can be found in Asia, the world's fastest-growing healthcare market. Hong Kong as a global financial, business and investment hub and gateway to Mainland China and Asia markets is the ideal base for international companies to seize new opportunities. It is the place to do business and the perfect location for International Healthcare Week."Addressing ASGH participants at the opening session, John Lee said: "Since taking office in July, my team and I have made substantive progress in lifting restrictions, while containing the number of confirmed cases and protecting the healthcare system and our high-risk population. We are working on specific and dedicated plans to ensure major events and economic activities can be held smoothly, to open up Hong Kong - to bring a world of business back to Hong Kong - as quickly, and as safely, as we can. This Summit, as well as last week's Global Financial Leaders' Investment Summit and Fintech Week, are welcome examples."Zsuzsanna Jakab added: "As COVID-19 has made clear, health, people's lives and the broader well-being of society are inextricably linked. Yet, COVID-19 has also exposed glaring global inequities. We have an opportunity, indeed an obligation, to learn from this pandemic and accelerate progress towards ensuring that more people benefit from universal health coverage, are protected from health emergencies and enjoy better health and well-being. The WHO will help countries connect and collaborate so that they can work as one team. We will make the greatest impact by working together."Cao Xuetao stated: "The National Health Commission will be actively supporting Hong Kong in three key areas: persevering in its control of the pandemic; strengthening Hong Kong's medical exchange and integration with the rest of the country; and giving full play to Hong Kong's healthcare talent and resources, which would allow it to participate in important national initiatives and make greater contributions to the work involved in connecting the country to the world and achieving the health goals of the UN's 2030 Agenda for Sustainable Development."Industry leaders share insights on latest healthcare and medical developmentsTo address the global impact of the COVID-19 pandemic and help prepare for future healthcare, economic and environmental challenges, this morning's ASGH plenary session "Charting a New Course in Healthcare through Collaboration" invited heavyweight speakers, including Ulrich Betz, Senior Vice President Innovation at Merck; Ruilin Song, Executive President of the China Pharmaceutical Innovation and Research Development Association; Luhan Yang, Co-Founder and CEO of Qihan Biotechnology; and Alex Zhavoronkov, Founder and CEO of Insilico Medicine. They examined the latest trends in the healthcare and medical sectors and the urgent need for global collaboration to strengthen healthcare cooperation for a sustainable future.A panel discussion titled "The Next Development in China's Healthcare Sector" was held on the first day, with Lo Chung-mau, Secretary for Health of the HKSAR, sharing his views on Hong Kong's role as a strategic conduit connecting Mainland China and the world in the healthcare arena. Additionally, Sun Dong, Secretary for Innovation, Technology and Industry of the HKSAR, delivered special remarks, sharing his valuable insights in a session titled "How Innovation in the Guangdong-Hong Kong-Macao Greater Bay Area Reshapes Global Healthcare". Peter Piot joined the summit and shared his expert perspective on how the world deals with healthcare challenges from Ebola to COVID-19. He is European Union (EU) Chief Scientific Adviser Epidemics and Special Adviser to the European Commission President and former Director and Handa Professor of Global Health of the London School of Hygiene & Tropical Medicine. In addition, the HKTDC and Haitong International published a joint research report on the future of the healthcare industry in Hong Kong and Mainland China.A plethora of online sessions will be staged tomorrow, covering important topics, such as preparedness for epidemic viruses, health equity, opportunities in the Asia market, the outlook for the biotech industry and medical robotic development. A number of industry leaders and experts have been invited to share their expertise at the summit.Holistic platform for project owners and potential investorsFollowing the success of last year's inaugural ASGH, a series of deal-sourcing and matchmaking sessions are taking place to meet the business matching needs of project owners and investors and generate new business opportunities. The exhibition area at ASGH included more than 180 exhibitors, including health innovation and technology companies, research and development institutions, incubation centres and more.More than 110 start-ups and projects are on view at the InnoHealth Showcase on-site. Live pitching sessions were organised where start-ups presented their innovations in transforming global healthcare and connected with potential investors and business partners for new business opportunities. Private equity and venture capital investors, family offices and high-net-worth individuals joined one-on-one online-to-offline meetings with project owners from around the world through ASGH Deal Flow Matchmaking. The summit also featured the Business of Healthcare Advisory Zone that provides a full range of advisory services to start-ups.Meanwhile, the 13th International Medical and Healthcare Fair featured the latest medical technologies and devices, healthcare and beauty products and related solutions and services.Themed zones showcase latest medical products and solutionsThe HKTDC Hong Kong International Medical and Healthcare Fair, co-organised with the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA), attracted more than 300 exhibitors from Hong Kong and different countries and regions, including seven local universities and pavilions formed by the HKMHDIA, the Hong Kong China Federation of Bodybuilding & Fitness and the Zhejiang Provincial Committee of the China Council for the Promotion of International Trade. The fair is held in hybrid format under the HKTDC's new EXHIBITION+ model. The physical show opened yesterday at the HKCEC and runs until 11 November, while exhibitors and buyers across the world can also connect through the smart business-matching platform Click2Match until 18 November.Under the theme of "Decoding MedTech Trends", the event features various zones, such as Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Product and World of Health and Wellness, alongside the Startup Zone. Exhibitors presented a wide array of products that highlight the latest medical trends and market demands, such as the ultrasonic Inofab Spiroclinic Pro - IoT Spirometer; the POD Telemedicine Health Checkup Station and a host of other products. Meanwhile, 24 start-up companies are displaying their accomplishments and solutions in the field of medical technology.The HKMHDIA MedTech Forum 2022 was held yesterday under the theme "Opportunities in the Greater Bay Area". Experts and representatives from the Department of Health of the HKSAR, the Department of Commerce of Guangdong Province, Johnson & Johnson, Konica Minolta and The University of Hong Kong-Shenzhen Hospital, among others, discussed topics, such as market opportunities for medical technologies in the GBA and innovative medical technologies. Industry professionals can watch videos of the events through the fair website ( https://bit.ly/3DNBBXy ). Also, seminars and workshops for industry players are being organised during the fair by the Hong Kong Doctors Union, the Golden Age Foundation and the Hong Kong Science and Technology Parks.The HKTDC has implemented its new EXHIBITION+ model to run the Hong Kong International Medical and Healthcare Fair. EXHIBITION+ comprises four key exhibition elements, including the physical fair, the smart business-matching platform Click2Match, online-to-offline seminars under the Intelligence Hub and the hktdc.com Sourcing platform, extending face-to-face interactions from physical exhibitions to an online smart business-matching platform to help enterprises connect with business partners proactively.Websites- International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en- Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en- Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme- Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker- Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en- Interesting Product List: https://bit.ly/3DOhppL- Activity Schedule: https://bit.ly/3DehRvF- Photo download: https://bit.ly/3A20Ow6About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedInMedia EnquiriesFor enquiries please contact:Asia Summit on Global HealthYuan Tung Financial Relations:Agnes Yiu, Tel: +852 3428 5690, Email: ayiu@yuantung.com.hkFung Wong, Tel: +852 3428 3122, Email: hfwong@yuantung.com.hkHKTDC's Communications & Public Affairs Department:Janet Chan, Tel: +852 2584 4369, Email: janet.ch.chan@hktdc.orgSam Ho, Tel: +852 2584 4569, Email: sam.sy.ho@hktdc.orgHong Kong International Medical and Healthcare FairHKTDC's Communications & Public Affairs Department:Frankie Leung, Tel: +852 2584 4298, Email: frankie.cy.leung@hktdc.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round ACN Newswire

Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round

November 1, 2022
HONG KONG, Nov 1, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital. This round of financing will facilitate ClinBrain to continuously deepen its expertise in the field of healthcare big data, explore the deep integration of big data and AI in the healthcare industry, promote the R&D of underlying technologies and scenario-based applications, and accelerate the promotion of industrial digital and intelligent upgrading.As a high-tech enterprise focusing on the healthcare big data intelligence platform, digitalized and intelligent application services, ClinBrain was shortlisted as the SDRI (specialized, refined, differential and innovative) "little giant" enterprise by the Ministry of Industry and Information Technology this year.At the beginning of its establishment in 2013, ClinBrain realized that healthcare, as a data-intensive and knowledge-intensive industry, is inseparable from the support of data, no matter in clinical services, operations management or medical research. ClinBrain has been committed to the direction of data governance and intelligent application of hospitals. By leveraging years of its industry experience and technical capabilities, the company has made breakthroughs in many fields, such as collecting data from hospital business systems without an interface, effectively identifying the data structure of complex business systems, effectively cleaning the business data of different versions and different manufacturers, forming effective and practical data quality rules to improve the data quality of hospitals, and conducting structured processing of unstructured data such as medical records and pathology. Moreover, with its powerful natural language processing (NLP) capabilities and robust rule and knowledge base, including more than 3900 data cleaning and quality rules embedded and tens of millions of medical concept term relationships accumulated, ClinBrain is also capable of automatically identifying the data structure of each version of more than 500 business manufacturers and realizing high-quality data cleaning and structured processing of unstructured data.LIU Huanchun, Chairman of ClinBrain, said, "Under the complex and volatile economic background and the ongoing pandemic situation, the recognition by many investors has reflected the market position, technological level and value of ClinBrain. After this round of financing, ClinBrain will promote the company's development to a new level by making further efforts in scientific and technological innovation and talent introduction."Raymond CHEN, Co-chief Investment Officer of Legend Capital, said, "Healthcare big data is a key driver of the digital and intelligent transformation of the pharmaceutical industry, which is in line with the long-term megatrend of new healthcare infrastructure. As a leading healthcare big data enterprise in China, ClinBrain provides full-link solutions from data governance to medical scenario applications based on its rich industrial theoretical knowledge and practical experience. We are optimistic that ClinBrain will create a new development form in healthcare big data by continuously expanding more products and customer application scenarios."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Inaugural International Healthcare Week promotes Hong Kong as leading healthcare hub ACN Newswire

Inaugural International Healthcare Week promotes Hong Kong as leading healthcare hub

October 31, 2022
HONG KONG, Oct 31, 2022 - (ACN Newswire via SEAPRWire.com) - Developments such as the COVID-19 pandemic and a global ageing trend have significantly increased the demand for healthcare products and services. The inaugural International Healthcare Week, driven by Hong Kong Trade Development Council (HKTDC), will run from 1 to 15 November 2022, helping to promote innovation, investment and exchange by fully utilising Hong Kong's strategic role as an innovation and investment hub for Asia's healthcare industry. The two flagship events of International Healthcare Week are the second Asia Summit on Global Health (ASGH) co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the HKTDC, and the 13th edition of the HKTDC Hong Kong International Medical and Healthcare Fair organised by the HKTDC.HKTDC Executive Director Margaret Fong; Prof Lo Yuk-lam, Chairman of GT Healthcare Capital Partners & President of the HK Bio-Med Innotech Association (L); Rupert Mok, Secretary General of Hong Kong Medical and Healthcare Device Industries Association (R)Yuan Hua Technology presents its research results at the press conference.Cellomics Holdings Limited features its product and service at the press conference.The two concurrent events encompass both upstream and downstream healthcare industries, from technology research and development, investment matching and medical device manufacturing, to medical products and services. Together they form a comprehensive one-stop platform to create synergies for medical and healthcare industry professionals.Margaret Fong, Executive Director of the HKTDC, said: "Since the pandemic, healthcare and the life sciences have become a global focus. From our work in promoting technology and medical devices over the years, we see that Hong Kong has considerable strengths in both the upstream and downstream elements of the healthcare, medical and life sciences ecosystem that can support the city in developing into a leading global healthcare and life sciences hub. In launching the first-ever International Healthcare Week this year, the HKTDC is inviting policymakers, healthcare experts, leaders in scientific discovery as well as business and financial leaders from around the world to share the latest industry knowledge and build business networks, and in the process cementing Hong Kong's position at the forefront of Asia's rapidly expanding healthcare industry."Building a sustainable post-pandemic futureThe second Asia Summit on Global Health will take place on 10 and 11 November. Activities on the first day will be held physically at the Hong Kong Convention and Exhibition Centre (HKCEC) with a live online broadcast, while the second day will be entirely virtual. Under the theme "Charting a New Course in Healthcare through Collaboration", the summit will feature more than 80 speakers including healthcare officials and organisations from around the world, international science and medical experts, investors, key industry players, business leaders, financial specialists and professional service providers. They are gathering to share their experience on the latest developments in public health, medical technology, international business collaboration and investment, and to explore future opportunities in the medical and healthcare industry.In the opening session, John Lee, Chief Executive of the HKSAR, will deliver the opening remarks, while Dr Zsuzsanna Jakab, World Health Organization Deputy Director-General, will address the summit as a guest speaker. Prof Lo Chung-mau, Secretary for Health, and Prof Dong Sun, Secretary for Innovation, Technology and Industry of the HKSAR, will also share their insights on how we can formulate more sustainable future policies on public healthcare and health innovation.Explore China's healthcare opportunities in the GBAIn the plenary session, "Charting a New Course in Healthcare through Collaboration", the speakers will discuss the role of Asia in the global development of the healthcare industry, as well as how stakeholders around the world can collaborate in preparation to address future challenges in terms of public health, the economy and environmental protection. In view of the rapidly increasing demand for high-quality healthcare and private hospital services, the panel discussion titled "The Next Development in China's Healthcare Sector" will see industry players gather to examine the latest trends and strategies in relation to healthcare investment and explore how to grasp investment opportunities in this rapidly growing market.The importance of the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) as a hub for advanced manufacturing, services, technology and innovation will be addressed in two sessions, namely "How Innovation in the GBA Reshapes Global Healthcare" and "Hong Kong as a Fundraising Hub for Global Biotechnology and Healthcare". Guest speakers including Thomas Herget, Head of Merck China Innovation Hub; Nicolas Aguzin, HKEX Chief Executive Officer; and Benjamin Xiaoyi Li, Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology Limited, will share on the importance of the GBA in reshaping global healthcare in the future, as well as the role of Hong Kong in helping the GBA to become a world-class health technology hub and mobilising capital for health research and innovation.The two-day summit will also feature Fireside Chats and Thematic Sessions, covering topics such as the development of China's healthcare sector, opportunities in the GBA and Asian markets under the Regional Comprehensive Economic Partnership (RCEP), the outlook for the biotech and genomics sectors, business opportunities in healthcare robotics, the application and ethics of artificial intelligence (AI) in healthcare, environmental, social and governance (ESG) development in the healthcare industry, health equity and mental health.Effective and professional platform to facilitate buying and selling of medical productsThe 13th edition of the HKTDC Hong Kong International Medical and Healthcare Fair opens in November at the Hong Kong Convention and Exhibition Centre (HKCEC), running in a hybrid format under the HKTDC's new EXHIBITION+ model. The physical fair runs from 9 to 11 November, while exhibitors and buyers can also connect through the smart business-matching platform Click2Match from 9 to 18 November.This year's fair, themed "Decoding MedTech Trends", has attracted more than 300 exhibitors from Hong Kong and different countries and regions, including companies from Canada, Mainland China, Korea and Taiwan, that will join under the physical and online format. Highlighted zones include Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care, World of Health and Wellness, along with the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA) pavilion's exhibition area and the Startup Zone. The zones will feature a range of the latest medical technologies and equipment, healthcare and beauty products, healthcare solutions and related services. The fair will provide the opportunity for industry professionals to get a comprehensive understanding of the latest trends in the medical industry as well as enabling them to source the latest products and services.Latest technologies and medical innovations on showThe fair will showcase multiple innovative medical and health-related products, including the Pocket Smartphone Ophthalmoscope, which is an ophthalmoscope that can be mounted over a smartphone camera, making it possible for caregivers to take fundus images of care recipients. The digital images are then sent direct to an ophthalmologist for diagnosis, making it quicker to detect eye-related problems and increasing the availability of early eye disease screening. The Implant Simulator, on the other hand, predicts the probability of different orthopaedic implant designs resulting in bone cracking. The system provides fast and accurate outcomes and has been used by five of the world's top 10 implant manufacturers. Another solution on show is AccuPos-Patient Tracking, a system that offers dashboard reports to caregivers in hospitals and elderly care centres for monitoring care recipients' locations in real time. Other featured products include 3D Anatomy Educational Software, the Robotic Flexible Endoscopic System, the Portable Digital Blood Pressure Monitor and many more. Six universities in Hong Kong, including the University of Hong Kong, the Chinese University of Hong Kong, the Hong Kong University of Science and Technology, the Education University of Hong Kong, the Hong Kong Baptist University and the Lingnan University, will also participate in the physical exhibition to showcase their achievements in innovation and technology for the healthcare industry.Twenty-two start-up enterprises will showcase their innovation and technology achievements at the show to capture new business opportunities. Various medical technology solutions will be on display, such as an advanced platform by HerBChain that uses blockchain technology to document supply chain data - from growing herbs to marketing herbal products - with the aim of improving the quality of herbs. Another innovation featured at the fair is the CTC100 Cell Sorting Platform that enables the isolation of circulating rare cells from blood to promote the early screening and treatment of cancer along with continuous monitoring for the benefit of patients.Industry professionals share insights at HKMHDIA MedTech ForumOrganised by the HKMHDIA in strategic partnership with the HKTDC, the HKMHDIA MedTech Forum 2022 will be held on the first day of the fair (9 November) at the HKCEC, accompanied by an online simulcast. Under the theme "MedTech Opportunities in the GBA", the forum has invited representatives from the Department of Health of the HKSAR Government and the Department of Commerce of Guangdong Province as well as industry experts from BGI Health (HK), HUAWEI Mobile Cloud, Johnson & Johnson, Konica Minolta, The University of Hong Kong-Shenzhen Hospital and UMP Healthcare Holdings, among others. They will discuss topics of key interest to the medical industry including medical technology market opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), the regulatory framework for medical devices, and innovative medical technologies. On 10 and 11 November, seminars and workshops on topics such as atrial fibrillation, medtech and applications of artificial intelligence will be staged by the Hong Kong Doctors Union, the Hong Kong Federation of Senior Citizen Industries and the Hong Kong Science and Technology Parks.Deal Flow Matchmaking, showcasing new medical and health innovationsDuring the two highlight events, a series of deal sourcing and matchmaking sessions will be held to help enterprises, start-ups, investors and buyers build connections and expand their businesses. The first day of the summit will feature Deal Flow Matchmaking which connects project owners with potential investors and business partners worldwide. The projects will cover the life sciences, medical devices and medications, AI and digital health, community health and more. The InnoHealth Showcase and exhibition area will be available on the first day of the event, featuring more than 180 healthcare start-ups and connecting them with potential investors or partners to explore new business opportunities.This year, the summit will feature six major local universities - The Chinese University of Hong Kong, Hong Kong Baptist University, City University of Hong Kong, the University of Hong Kong, the Hong Kong University of Science and Technology and Hong Kong Polytechnic University - to showcase their start-ups and inventions on-site, with organisations such as the Innovation and Technology Commission (ITC), Cyberport, and NAMI acting as Health Innovation Partners. The ITC is featuring 17 healthcare-related research and development (R&D) centres under its InnoHK initiative to demonstrate Hong Kong's strength as a global innovation powerhouse. Project pitching and various other activities will be held physically and virtually to highlight next-generation start-ups and projects in order to connect them with potential investors and partners worldwide.In addition, biotechnology and healthcare start-ups can take advantage of the Business of Healthcare Advisory Zone on-site or online on the first day of the summit. Investors and industry experts will be at hand to provide a full range of professional consulting services, including fundraising, R&D cooperation, intellectual property licensing arrangements, market access and distribution models, as well as incubation services to help start-ups formulate business strategies.EXHIBITION+ helps exhibitors find business partners and expand opportunitiesThe Hong Kong International Medical and Healthcare Fair will run under the new EXHIBITION+ model. It comprises four key exhibition elements, including the HKTDC-organised physical fair, the smart business-matching platform Click2Match, online-to-offline seminars under the Intelligence Hub, and the hktdc.com Sourcing platform, extending face-to-face interactions from physical exhibitions to an online smart business-matching platform to help enterprises connect with business partners proactively.In addition to the two highlight events, the first International Healthcare Week will also feature other related events including the Gerontech and Innovation Expo cum Summit 2022, the Hong Kong Urological Association 27th Annual Scientific Meeting and the Hong Kong International Optometric Symposium.Websites- International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en- Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en- Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme- Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker- Hong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/en- Interesting Product List: https://bit.ly/3DOhppL- Activity Schedule: https://bit.ly/3DehRvF- Industry facts and figures supplementary sheet: https://bit.ly/3WhQF83- Photo download: https://bit.ly/3fjoDZ8Members of the media interested in interviewing ASGH speakers can send an email to janet.ch.chan@hktdc.org or ayiu@yuantung.com.hk on or before 8 November.About HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn.Media EnquiriesFor enquiries please contact:Asia Summit on Global HealthYuan Tung Financial Relations:Agnes Yiu, Tel: +852 3428 5690, Email: ayiu@yuantung.com.hkFung Wong, Tel: +852 3428 3122, Email: hfwong@yuantung.com.hkHKTDC's Communications & Public Affairs DepartmentJanet Chan, Tel: +852 2584 4369, Email: janet.ch.chan@hktdc.orgSam Ho, Tel: +852 2584 4569, Email: sam.sy.ho@hktdc.orgHong Kong International Medical and Healthcare FairHKTDC's Communications & Public Affairs Department:Frankie Leung, Tel: +852 2584 4298, Email: frankie.cy.leung@hktdc.org Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
2022 Seongnam Global Healthcare Convention will be held from Oct. 27,2022 to Oct. 29, 2022 SeaPRwire

2022 Seongnam Global Healthcare Convention will be held from Oct. 27,2022 to Oct. 29, 2022

October 20, 2022
Making a leap forward as the Fourth Industrial Innovation City Seongnam, Korea,October20, 2022- (SEAPRWire) – Seongnam City will host the ‘2022 Seongnam Global Healthcare Convention’ at the City Hall from October 27 to 29. Seongnam Global Healthcare Convention (formerly Seongnam International Medical Tourism Convention), which marks its fifth anniversary, will be organized as an online and offline event to promote Seongnam City’s medical tourism and healthcare industries at home and abroad, combining fourth industrial technologies such as artificial intelligence and big data. The city will hold events for three days including Exhibition on Seongnam Medical Tourism and Healthcare (Oct. 27-29, City Hall lobby and outdoor plaza), B2B Meetings (Oct.27-28, City Hall 3F, Hannuri), International Conference (Oct. 27-28, City Hall 1F, Onnuri), and Lectures on Health & Wellbeing for the Public (Oct.29, City Hall 1F, Onnuri), starting with the opening ceremony at Onnuril of City Hall at 10 a.m. on the first day of the convention. The online participation window includes the official website of Seongnam Global Healthcare Convention and YouTube(channel name: Seongnam Medical Tour). The exhibition event will showcase a variety of items such as artificial intelligence medical services, digital healthcare, concierge (hotel, travel, shopping) products, beauty, quarantine, pharmaceutical & bio, and medical devices from 82 participating institutions and companies. The event will carry out promotional marketing targeting buyers from 44 companies from 14 countries visiting the convention site, including a global big buyer iHerb, a U.S. overseas direct purchase platform as well as CVS Health, a major pharmacy franchise representing the U.S., The B2B Meetings will be operated in such a way that companies participating in the exhibition meet with buyers from 74 companies in 20 countries including the U.S., Austria, and Singapore, and have export consultations. The International Conference will be attended by 20 domestic and foreign experts in the field of medical tourism and healthcare. In the field of medical tourism, there will be topic presentations on the: Pioneering a new market for the sustainable development of medical tourism in South Korea (Ki-nam Jin, Professor, Yonsei University).Medical tourism marketing of Bumrungrad International Hospital (Napas Paorohitya, Chief Marketing Officer, Bumrungrad International Hospital).Medical Tourism Strategy for Malaysia(Talent Management Consultant, Thomson Hospital Kota Damansara). In the field of healthcare, there will be topic presentations on the: Data-based hyper-personalized mobile health care service (Hee Hwang, CEO, Kakao Healthcare).2017/745 EU medical device regulations and certification future trends(Soo-hyuk Uhm, Clinical Assessor, DNV). Through each presentation, changes in the medical tourism and healthcare sectors brought by COVID-19 are diagnosed and future strategies are suggested. Lectures on the Health and Wellbeing for the Public is hosted by comedian Dae-hee Kim, and five lectures will be given by doctors, oriental medicine doctors, and professors, including “Diabetes and blood sugar management,” “The introduction of turtle neck & straight neck and correctional exercise method”, “How to get pregnant in a proper way”, “My inner child” and “Protect myself with ways of thinking: Mental healthcare constants and variables”. A city official said, “Seongnam area has the best medical tourism infrastructure in the country, including 1,707 hospitals, 19,100 medical personnel, and 660 advanced bio and healthcare companies.” adding, “We will promote globalization by creating a foothold to become a 4th industrial innovation city through this event.” Media Contact Brand: 2022 Seongnam Global Healthcare Convention Contact: hee-joo Jin Email: 2022smcbiz@simtc.org Website: http://www.simtc.org SOURCE: 2022 Seongnam Global Healthcare Convention The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong ACN Newswire

EC Healthcare Acquires Multi-Disciplinary Healthcare Services Chain in Hong Kong

October 3, 2022
HONG KONG, Oct 3, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group and the Seller enters into a sale and purchase agreement to acquire 60% of the issued share capital of Pioneer Evolution Limited (the "Target Company") for a total consideration of HK$36.4 million in cash. The Target Company is a controlling holding company of a medical service provider which has a long-standing history in providing multi-disciplinary healthcare services in Hong Kong since 2002 and operates 9 medical centers under the business name of Sure-Care Medical and Health Network. Sure-Care Medical and Health Network has an extensive geographic coverage over Kowloon, New Territories and HK Island, including Mong Kok, Tai Po, Causeway Bay, Tsuen Wan and Jordan. Sure-Care Medical and Health Network also has a professional medical team of over 23 registered medical practitioners and covering 8 medical specialties and general medical services. According to the unaudited consolidated financial information, the profit after tax of the Target Company was approximately HK$5.9 million for the six months ended 30 June 2022 and HK$12.1 million for the year ended 31 December 2021. Upon completion of the acquisition, the financial results of the Target Company will be consolidated into the consolidated financial statements of the Group. The Seller guarantees to the Group with an accumulated net profit for the five years ending 31 December 2027 should be no less than HK$70 million. The acquisition of the multi-disciplinary healthcare services is expected to deepen the Group's medical services layout and enable the Group to further increase its market share in the healthcare market. Upon the completion of the acquisition, the Group's full time registered doctor team will be expanded and the Group's medical services capability will be further strengthened in Hong Kong, particularly in New Territory East and expected to create cross referral to increase market share. Leveraging on the Group's operational excellence and efficiencies, the Group will empower Sure-Care Medical and Health Network to improve its asset value through corporatization. Mr. Levin Lee, Executive Director and Chief Finance Officer of EC Healthcare, said, "EC Healthcare is always committed to building up an enclosed ecosystem to provide premium services to the client by leveraging multiple brands and disciplines. The acquisition is aligned with the Group's expansion strategy and will further consolidate the Group's leading market position in Hong Kong's healthcare market, maximizing overall shareholders' return. EC Healthcare will continue to be the leading market consolidator and develop its businesses through organic growth and mergers and acquisitions and strive to be the Asia leading healthcare services provider."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Tim Tin / Sophia Wu Tel: (852) 2136 6952 / 2169 0467 / 3920 7654 / 3920 7645Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Corinium presents: Data & Analytics in Healthcare Online ASEAN ACN Newswire

Corinium presents: Data & Analytics in Healthcare Online ASEAN

September 28, 2022
Singapore, Sep 28, 2022 - (ACN Newswire via SEAPRWire.com) - Join Corinium's Data and Analytics in Healthcare ASEAN on October 18 and learn how healthcare can use data and analytics to revolutionise patient experience. Attracting everyone from hospitals to government, insurers to community health, you will hear how the leading minds in healthcare are making actionable insights from their huge data sets. Through a range of cutting-edge case studies and presentations, issues tackled will include data governance, data-driven decision-making, predictive analytics, data integration and automation, patient turnaround improvement, digital transformation implementation in healthcare, and data-centric culture embedding.Join this sensational line up of healthcare data experts as we explore the lessons learned and bright future as we use data to revolutionise patient outcomes.2022 Key Themes: Innovation and Data-Drive Success - This theme looks at how innovative data management can drive success.Decision-Making Using Data and Technology - The influence of data and analytics in making better and more sustainable decisions is a proved strategy for business performance. This theme will touch on decision-making and planning through data to deliver better patient outcomes and built a resilient healthcare organisation.Transformative Analytics for Patient Care - A critical theme to Data & Analytics in healthcare is the delivery and implementation strategies that enables organisations to grow with data.Claim Your FREE Place Today! We cannot wait to host you online during the event for this event full of inspiration, collaboration, and innovation. For Further details regarding this event, visit our website:https://datainhealthcare-asean.coriniumintelligence.com/ You can contact us at: info@coriniumintel.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Mediwelcome Announced 2022 Interim Results ACN Newswire

Mediwelcome Announced 2022 Interim Results

September 23, 2022
HONG KONG, Sep 23, 2022 - (ACN Newswire via SEAPRWire.com) - A China's leading provider of digital medical service solutions - Mediwelcome Healthcare Management & Technology Inc. ("Mediwelcome" or the "Company", and together with its subsidiaries, the "Group") (Stock Code: 2159), announced the unaudited consolidated interim results for the six months ended 30 June 2022 (the "Reporting Period" or the "First half of 2022"). In the first half of 2022, Mediwelcome has narrowed in revenue and other aspects to varying degrees due to the continuous lockdown in many provinces in response to the severe pandemic in the PRC. In the first half of 2022, Mediwelcome's revenue decreased by approximately 49.2% to approximately RMB172.5 million YoY. Gross profit was approximately RMB17.3 million. During the Reporting Period, the Group's primarily generated revenue from medical conference services, marketing strategy and consulting services, and patient education and screening services, etc.Continuously expanding the medical digital marketing solutions and online healthcare platforms, and striving for digital upgradingAlthough the economic environment is facing great challenges under the epidemic situation, Mediwelcome always insists on continuously expanding and consolidating its integrated healthcare marketing solutions and made a concerted effort to develop its online healthcare platforms and fully implemented digital upgrade for the businesses. During the Reporting Period, medical conference services was the main revenue stream and recorded revenue of approximately RMB111.3 million, accounting for 64.5% of the total revenue. To strengthen the Group's conference management capabilities, Mediwelcome has launched the Conference+ App for medical NGOs and pharmaceutical companies to submit onsite conference requests and monitor conference implementation. In terms of marketing strategy and consulting services, through this service, the Group assisted pharmaceutical companies in formulating and implementing effective business strategies in enhancing their brands and product awareness among physicians. During the Reporting Period, marketing strategy and consulting services recorded revenue of approximately RMB41.3 million, accounting for 23.9% of the total revenue. Patient education and screening services and CRO services recorded revenue of approximately RMB14.3 million and RMB3.7million, accounting for 8.3% and 2.1% of the total revenue, respectively.As of June 2022, the Group has developed and iterated multiple medical digital marketing platforms and products to provide customers with customised medical digital marketing solutions, including the Giraffe Smart Medical Platform, Digital Patient Management Platform, E Conference, Giraffe Live, Deer Class, E Creation, E Insight and other products. As at 30 June 2022, the digital platforms have enrolled 384,965 registered doctor users, held 46,518 online education sessions with doctors and 25,687 online education sessions for patients, livestreamed 4,855 times, with 6,319 videos available and viewed by 1,086,328 visitors.Meanwhile, Mediwelcome has sustained its effort to develop and expand its online healthcare platforms to cater for the increasing needs of various stakeholders in the medical field, including hospitals, doctors as well as pharmaceutical and medical equipment companies. The Group's online healthcare platform, on top of providing doctors and patients with consistent and quality online medical service solutions, has also actively developed products and services of digital management for patients with chronic illnesses in the out-of-hospital context. As at 30 June 2022, the number of its registered doctor and patient users has reached 45,244 and 200,545, representing an increase of 69.9% and 321.2% YoY, respectively. In addition, due to the increase in the number of active patient users purchasing prescribed medicine through the Group's internet hospital platform, revenue from internet hospital services increased by approximately 5.6% to approximately RMB1.9 YoY.Continuously upgrading the digital marketing business, seizing the growth opportunities to create greater valueLooking forward, Mediwelcome will continue to enhance the scale of digital marketing business, and utilize its internal and external strengths and resources and focus more on customer development for digital marketing in the healthcare market. At the same time, the Group will sustain its effort to build a digital platform with precise access targeting doctors and patients, providing customers with integrated digital and intelligent marketing solutions using a digital integrated marketing system synergised by both offline and online channels, so as to create a closed loop for the whole process of digital operation. The Group will continue to upgrade its online healthcare platform and explore the application of AI technology to build a closed-loop business model from inside to outside hospitals. In addition, Mediwelcome will also leverage the favorable health policy environment and its own resources to maintain revenue growth of its professional medicine and marketing services in the traditional cardiovascular and cerebrovascular discipline, with a focus on expanding its business in the fields of oncology and chronic renal diseases to increase the coverage of customers from domestic enterprises.The Group will continue to maintain its business scale in the traditional dominant therapeutic fields, and actively drive innovation in order to seize the opportunities arising from the rapid growth in demand for medical digital marketing and online healthcare for its steady development. While actively generating profits under its efficient operation, the Group persistently expands and develops its business model and scale to create greater value for more customers, doctors and patients. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Corinium presents: CISO Healthcare APAC Online ACN Newswire

Corinium presents: CISO Healthcare APAC Online

September 19, 2022
Singapore, Sep 19, 2022 - (ACN Newswire via SEAPRWire.com) - Exclusively designed for today's healthcare InfoSec leaders to compare their strategies and to learn, network with forward-thinking peers, to discuss how the healthcare industry can use information security to reform and revolutionise the patient experience.Taking place across two days, this online event delivers the content you cannot find anywhere else. Are you ready to accelerate your data and analytics journey?The conference will cover a range of cutting-edge case studies and issues tackled will include data governance, data privacy and consent!CISO Healthcare Online APAC provides the unique opportunity to connect, learn, and do more business, effectively, safely and with confidence.Join us, 22-23 November, for over two action-packed days and the event will bring together infosec leaders from key healthcare providers across the region!2022 Key Themes: - Threats to Healthcare Information Exploring the vulnerabilities of information system in healthcare through case studies and what was done in the past to mitigate risks- Digitalisation of Healthcare Exploring the risks and benefits of digitalisation and virtual care services, and how to deploy them securely- Cybersecurity as a Shared Responsibility Supporting and educating healthcare workers on ways to keep information safe and steps to respond to an attack- Building a Resilience Healthcare Information System Preparing your security plan, process, and governance by taking into account new risks and threats and implementing different strategies to safeguard vulnerabilitiesClaim your FREE place today! We cannot wait to host you online during the event for two days of learning, sharing, and networking!For Further details regarding this event, visit our websitehttps://cisohealthcare.coriniumintelligence.com/ You can contact us at: info@coriniumintel.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare Chairman Mr. Eddy Tang Further Increases Shareholding, Exhibiting Unwavering Assurance in the Future Development of the Group ACN Newswire

EC Healthcare Chairman Mr. Eddy Tang Further Increases Shareholding, Exhibiting Unwavering Assurance in the Future Development of the Group

September 9, 2022
HONG KONG, Sep 9, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that on 7 September 2022, the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai further acquired a total of 170,000 shares of the Company on the open market for approximately HK$854,800 at an average price of HK$5.0282 per share. Prior to this transaction, Mr. Tang had already increased his shareholding in the Company earlier this month on 1 September 2022, acquiring a total of 107,000 shares at an average price of $5.4905 per share. After the transaction, Mr. Tang holds an aggregate of 722,204,610 shares in the Company, increasing his equity stake from 61.27% to 61.29%.Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "In spite of the current economic climate, we are confident that the medical market will remain resilient and that long-term public-private healthcare partnerships will continue to drive up investment in Hong Kong's private healthcare sector. Reaping the benefits from its ongoing investments in elevating healthcare service offerings, the Group exemplified solid business recovery by delivering first-quarter sales volume of no less than HK$860 million for the financial year that concluded on March 31, 2023. Management is still nevertheless upbeat about the Group's business success going forward. In order to continue enhancing EC Healthcare's enclosed healthcare ecosystem, the Group will go forward with its close collaboration with the major players in the technology, telecommunications, insurance, property, and pharmaceutical industries."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre EC DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare and AXA Jointly Establish the FIRST AXA Medical Centre ACN Newswire

EC Healthcare and AXA Jointly Establish the FIRST AXA Medical Centre

September 8, 2022
HONG KONG, Sep 8, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group has entered into a non-legally binding memorandum of understanding (the "MOU") with AXA Hong Kong & Macau ("AXA") for a strategic partnership, pledging to work together to provide premium and comprehensive health management services to customers. EC Healthcare and AXA signed Memorandum of understanding today to kick start their long term collaboration. (From left: Emily Li, Chief Employee Benefits & Wellness Officer, AXA Hong Kong and Macau, Sally Wan, Chief Executive Officer of AXA Greater China, Eddy Tang, Founder, Chairman, Executive Director and CEO of EC Healthcare and Leslie Lu, Executive Director and Co-CEO of EC Healthcare)Under the partnership, the first AXA Medical Centre was unveiled today on the 34th floor of the World Trade Centre in Causeway Bay. Together with the AXA designated Endoscopy and Day Surgery Centre in Central, it will officially start operating in November this year.Located in the central business district of Causeway Bay, the AXA Medical Centre occupies a floor area of over 5,000 sq. ft. The center offers services include preventive medicine, body checks, vaccinations, and nutritional counselling with support from on-site medical professionals including general practitioners, Chinese medicine practitioners, dieticians and radiographers. The AXA Medical Centre provides various body check services such as chest and abdominal X-rays, ultrasound scans, gynaecological examination, electrocardiogram (ECG) with over 10 body examination rooms. Other services include allergy tests, non-invasive genetic screening tests for colorectal cancer, and all pre-insurance health screening for AXA customers.EC Healthcare is building a one-stop, multi-disciplinary, enclosed healthcare service platform, which allows AXA's customers to obtain a seamless medical referral service after check-ups and enjoy comprehensive, high-quality medical services that covers multiple medical disciplines.In addition to setting up dedicated medical centres, the Group and AXA will further their cooperation with a view to extending the market coverage of their services to other central business districts and residential areas.Mr. Leslie Lu, Executive Director and Co-CEO of EC Healthcare said, "Hong Kong's private healthcare market has huge potential. The Group regards strategic partnership with insurance firms as a key strategy of building up its presence in the growing market. The Group is very honoured to form partnership with such an internationally leading insurance group as AXA. The Group believes that the strategic partnership will boost higher customer public traffic with strong synergy in the healthcare sector and enhance the organic growth of the Group's medical and healthcare business through the provision of high-quality and high-end branding medical and healthcare services. The Group will also forge ahead with its deep strategic cooperation with the key players in the technology, telecommunications, insurance, property and pharmaceutical industries so as to keep enriching EC Healthcare's enclosed healthcare ecosystem."Ms. Sally Wan, Chief Executive Officer of AXA Greater China said, "AXA Medical Centre marks a major milestone for us in delivering exceptional health management services to our customers, providing our customers with all-round care across their life stages. The centre, offering comprehensive one-stop health management services spanning prevention, diagnosis, and treatment, not only enhanced AXA's health management ecosystem but also brought to life our ongoing commitment to become a lifelong partner to our customers. AXA and EC Healthcare share the same vision of improving our customers' holistic wellness. Through this partnership, we can bring an exclusive, innovative, and personalised healthcare experience beyond insurance to our customers leveraging our combined strength."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk Tel: (852) 2136 6952 / 2169 0467 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare Chairman Mr. Eddy Tang Increases Shareholding, Demonstrating Full Confidence in the Group’s Future Development ACN Newswire

EC Healthcare Chairman Mr. Eddy Tang Increases Shareholding, Demonstrating Full Confidence in the Group’s Future Development

September 2, 2022
HONG KONG, Sep 2, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that on 1 September 2022, the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai had acquired a total 107,000 shares of the Company on the open market for approximately HK$587,000 at an average price of HK$5.4905 per share. After the transaction, Mr. Tang holds an aggregate of 722,034,610 shares in the Company, increasing his equity stake from 61.26% to 61.27%.Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "Benefitting from the result of its continuous investment in IT, brand and service, the Group recorded a sales volume of no less than HK$860 million in the first quarter of the financial year ended 31 March 2023 (April to June 2022). This shows a good recovery in its business. EC Healthcare will continue to consolidate the healthcare market through organic growth and acquisitions and thus reinforce its leading market position. The Group believes that the medical market will remain resilient in the challenging business environment and that public-private partnerships in healthcare will keep boosting spending in the market of Hong Kong's private healthcare sector in the long run. Looking ahead, the management remains optimistic about the Group's business performance. The Group will also forge ahead with its deep cooperation with the key players in the technology, telecommunications, insurance, property, and pharmaceutical industries so as to keep enriching EC Healthcare's enclosed healthcare ecosystem."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre EC DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine IpTel: (852) 2136 6952 / 2169 0467 / 3920 7649Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
CT Event Asia to host ASEAN Healthcare Transformation Summit 2022 ACN Newswire

CT Event Asia to host ASEAN Healthcare Transformation Summit 2022

September 1, 2022
KUALA LUMPUR, Sep 1, 2022 - (ACN Newswire via SEAPRWire.com) - This year, CT Event Asia is all set to bring you the Asean Healthcare Transformation Summit 2022, themed "Leveraging Human Touch and Technology in the Era of Connected Health". Happening at the JW Marriot Hotel on 6th-7th September 2022, this conference is the most interactive healthcare summit in Southeast Asia, aims to address the most pressing issues in the healthcare sector. The summit promises to be even larger and will feature keynotes sessions emphasizing on the digital health ecosystem, public health systems transformation, universal health coverage, robots in healthcare, integrated hospitals and burnout in HCW. This summit will be supported by 4 focused streams on 'healthcare digitalisation & innovation', 'value based & patient centered care', 'patient safety & quality' as well as 'lean management & operations excellence'. We are anticipating over 500+ participants from utility leaders, Hospitals, Government agencies, Pharmaceutical, Solution providers, IT and Investors to discover the healthcare landscape, transformation solutions in healthcare, emerging trends in the industry and new health-tech to stay relevant in your profession in a challenging and complex operating environment. Here is our speaker list!Join us now to get more insights from the healthcare industry leaders and meet our Sponsors and Partners as well with all of this to explore, our Asean Healthcare Transformation Summit 2022 is set out to be bigger than ever! Here's our list of Sponsors and Partners.The Asean Healthcare Transformation Summit 2022 website has full details about the program. Interested parties can visit the website here or request for the event brochure here. To get in touch with our team for enquires relating to this event, feel free to reach out to:CamaraPartnership Director CT Event Asia+60 16 283 2660 | +03 2710 7756camara@cteventasia.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Avantor and Avantor Foundation Make a Difference by Providing Critical Health Services for Vulnerable Communities in Singapore ACN Newswire

Avantor and Avantor Foundation Make a Difference by Providing Critical Health Services for Vulnerable Communities in Singapore

August 24, 2022
Singapore, Aug 24, 2022 - (ACN Newswire via SEAPRWire.com) - Avantor Foundation, Avantor's philanthropic arm, committed financial resources to healthcare charitable organizations, HealthServe and SATA CommHealth, as part of the Foundation's mission to provide healthcare to those in need. The grants will offer much-needed support to communities who would otherwise be unable to receive quality medical care. By identifying community needs and addressing them through these grants, the Avantor Foundation is able to contribute to the advancement of healthcare in Singapore and the region."As we continue to create a better world, grants like this demonstrate our commitment to providing healthcare to those in need," said Christophe Couturier, Executive Vice President, AMEA, Avantor and Board Member of the Avantor Foundation. "By working with SATA CommHealth and HealthServe, we want to connect and help communities, which deserve crucial assistance but are sometimes overlooked. The aid we are providing will address the critical unmet needs in healthcare and enable Science for Goodness, and ultimately create a lasting impact in our communities."SATA CommHealth, an organization which serves the community through the provision of subsidized care in their medical centers, will work with approximately 50 community and grassroots organizations to provide free health screenings for the elderly and less fortunate through regular check-ups and early medical intervention to prevent chronic or deadly diseases."We are truly grateful to receive this generous donation from the Avantor Foundation," said Boon Khiang Chia, Director & Head of Strategic Partnerships & Branding, SATA CommHealth. "We will be able to facilitate collaboration with our community leaders and constituency representatives to effectively serve the healthcare needs of our beneficiaries, especially the elderly who are most vulnerable to poor health."The Avantor Foundation also has provided a grant to HealthServe, a medical NGO that advocates for the needs and wellbeing of vulnerable, low-wage migrant workers in Singapore. Their services include healthcare, counseling, casework, mental health support and social assistance for their beneficiaries. HealthServe will use this grant for a nurse-led chronic disease case management program that supports migrant workers in need of medical assistance. Michael Cheah, Executive Director, HealthServe said, "Bringing healing and hope to migrant workers has always been a cause that is very close to our hearts. This contribution from the Avantor Foundation will allow us to offer customized care plans to these workers in need of medical assistance and deliver better care outcomes for them in the long term."About AvantorAvantor, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit www.avantorsciences.com/site/ and find us on:LinkedIn - https://www.linkedin.com/company/avantorinc/Twitter - https://twitter.com/Avantor_NewsFacebook - https://www.facebook.com/Avantorinc/About Avantor FoundationAs the philanthropic arm of Avantor, the Avantor Foundation's mission is to create a better world by advancing science education and providing healthcare to those in need. Since 2009, the Avantor Foundation has been making a difference in the science community by supporting organizations aligned to its mission. Learn more at www.avantorsciences.com/pages/en/avantor-foundation.Media ContactChristina KohDirector, Communications - AMEAAvantorM: +65 9720 0169Christina.Koh@avantorsciences.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Digital Health and Technology Trends in the USA ACN Newswire

Digital Health and Technology Trends in the USA

August 1, 2022
AUSTIN, TX, Aug 1, 2022 - (ACN Newswire via SEAPRWire.com) - What role and purpose will businesses accept to impact the social contract, and how might consumer and provider empowerment might bring change to healthcare business models using technology?The Partners in Digital Health blockchain in healthcare and telehealth portfolio both reflect and set trends in the marketplace. Here are a few trends and current issues to ponder.Cost, place, and preference have prioritized the care at home care and care transitions as aging populations and a looming healthcare worker shortage impact the US health system, where virtual care presents an opportunity to build long term resilience into system.Adopting Zero Trust Architecture to enhance security across agencies and businesses must quickly be adopted, following the executive order on improving the Nation's Cybersecurity (EO 14208). If you've been hacked recently, you understand the urgency.A fully realized digital 3D world (Web3/Metaverse), creating virtual holographic experiences, including digital twins that operate in real-time, must be created for secure use. Healthcare is at the forefront with medical education initiatives and holoportation. Ambient AI, or real-time human perception technology, that enables intelligent environments is an area where technology can anticipate and respond to people's needs, customize and forecast behaviors across the continuum of care - and reduce the cost of care. Compliant AI-powered conversational patient intake can also increases time and quality time engagement with patients.Diversity and inclusion present new market opportunities for drug discovery, startups, apps, payment models, cross boarder collaborations, market investment and more. Pandemics teach us there are significant differences in patient populations with sexual, cultural, age, and geographic diversities to consider.The cash economy in healthcare is on the rise. A retail health revolution is occurring where employers give their employees cash instead of health insurance. Consumers pay cash for drugs and services that are cheaper than those covered through insurance - and participants don't have to deal with system bureaucracy.Price transparency for health insurance market plans to make hospital pricing transparent for patients to compare costs for care is embraced by 85% of Americans. Consumers believe cost cutting and improving quality through transparency should be a priority. Site neutral payments are another way to level the playing field and could save the USA as much as $350 billion over the next decade.Cryptography and applying quantum mechanics for uncrackable code for two parties to interact securely. The US is teetering on losing its competitive edge and may have already. Blockchain will improve how the public interacts with government services and will have broad economic and social implications. Global health passes and interoperable permissioned global networks are examples and only the beginning of the wave impacting healthcare.At ConV2X, just about every facet of blockchain technology is explored including cybersecurity and quantum computing, patient experiences, credentialing, data ownership, Metaverse, NFTs, DAOs, TradFi, privacy protection, joint workflows and processes, inventory management, fraud, chargebacks, precision medicine, zero trust frameworks, standards and more.A real revolution of borderless interoperability, led by consumers, activists and pioneers, challenging market integrity and sensibilities is well underway.For more information visitBlockchain in Healthcare Today (https://blockchainhealthcaretoday.com/index.php/journal) journal, or ConV2X Blockchain in Healthcare 2022 (https://conv2xsymposium.com/registration/) eventTelehealth and Medicine Today (https://telehealthandmedicinetoday.com/index.php/journal) journal, or ConV2X Telehealth 2022 (https://telehealth2022.conv2xsymposium.com) event Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More